Products
The Spanner™Prostatic Stent has received CE Mark and FDA approval and is currently
marketed in the U.S. and abroad. The American Medical Association (AMA) has established Category I CPT®* code 53855 for the insertion of a temporary urethral stent for the prostate, including urethral measurement. The Spanner stent has been designed to open the prostatic urethra and allow patients to maintain urine flow and experience volitional voiding by reducing urethral resistance within the prostate. The Spanner stent is an alternative for some patients** to indwelling Foley catheterization, clean intermittent catheterization, or a suprapubic tube.
*CPT® is a registered trademark of the American Medical Association.
** CE Mark Indications: The Spanner is indicated for temporary use (≤ 90 days) in men with bladder outlet obstruction (BOO) to reduce elevated post void residual (PVR) and improve voiding symptoms. FDA Indications: The Spanner Temporary Prostatic Stent is intended for temporary use (up to 30 days) to maintain urine flow and allow voluntary urination in patients following minimally invasive treatment for benign prostatic hyperplasia (BPH) and after initial post-treatment catheterization.
The Surveyor™ urethral measurement device is designed to assess the length of the urethra from the bladder neck to the external sphincter. Use of The Surveyor permits correct stent size selection.
Other products to benefit men with lower urinary tract symptoms are currently under development.
